Global /Japan /Healthcare /Drug Manufacturers - General /4591

Ribomic Inc.

4591

• TSE: 4591 • Delayed

79JPY 0%

0.4926 USD

As of 13 June 2026, Ribomic Inc. has a market cap of $26.8M USD, ranking #35021 globally and #3352 in Japan. It ranks #3159 in the Healthcare sector, and #1068 in the Drug Manufacturers - General industry.

Global Rank

35021

Country Rank

3352

Sector Rank

3159

Industry Rank

1068

Key Stats

Market Cap

$26.8MUSD

4.29B JPY

Enterprise Value

$6.8MUSD

1.09B JPY

Revenue (TTM)

$4.69KUSD

750.0K JPY

EBITDA (TTM)

-$6.65MUSD

-1.07B JPY

Net Income (TTM)

-$6.51MUSD

-1.04B JPY

PS Ratio

5720.5

PB Ratio

1.3

Company Profile

Country (HQ)

Japan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Yoshikazu Nakamura open_in_new

Employees

Founded

2003

Website

ribomic.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-4.8%	-16%	-6%	-11%	1.3%	-14%	-55%	-76%

News

Markets

Exchange	Ticker	Price	Quotes
Tokyo Stock Exchange (TSE / TYO) MIC: XTKS PRIMARY	4591 株式会社リボミック ISIN: JP3974850004 Shares Out.: Shares Outstanding: 55.949M¹ Shares Float: 53.848M² TV: TradingView: TSE: 4591 SA: Stock Analysis: TYO: 4591 YF: Yahoo Finance: 4591.T GF: Google Finance: TYO: 4591 BA: Barron's: 4591 MS: Morningstar: XTKS: 4591	79 JPY	TV: TradingView: TSE: 4591 SA: Stock Analysis: TYO: 4591 YF: Yahoo Finance: 4591.T GF: Google Finance: TYO: 4591 BA: Barron's: 4591 MS: Morningstar: XTKS: 4591

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Ribomic Inc.

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. The company was incorporated in 2003 and is headquartered in Tokyo, Japan.

Similar Companies

Industry: Drug Manufacturers - General (Japan)

Name	Market Cap (USD) diff.	PE	Country
Chugai Pharmaceutical Co., Ltd. TSE: 4519	$81.63B 13.07T JPY 304K%	28.9	Japan
Takeda Pharmaceutical Company Ltd. TSE: 4502	$52.2B 8.36T JPY 195K%	75.1	Japan
Otsuka Holdings Co., Ltd. TSE: 4578	$36.83B 5.9T JPY 137K%	15.7	Japan
Daiichi Sankyo Company, Ltd. TSE: 4568	$30.36B 4.86T JPY 113K%	16.2	Japan
Astellas Pharma Inc. TSE: 4503	$25.81B 4.13T JPY 96K%	14.2	Japan
Shionogi & Co., Ltd. TSE: 4507	$16.9B 2.71T JPY 63K%	13.9	Japan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 3M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 2M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 1M%	97.4	United States
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 1M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 1M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 1M%	20.5	Switzerland

chevron_leftBack